{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:30:59Z","timestamp":1787740259330,"version":"build-2784847793"},"reference-count":107,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Genome editing holds the promise of one-off and potentially curative therapies for many patients with genetic diseases. This is especially true for patients affected by mucopolysaccharidoses as the disease pathophysiology is amenable to correction using multiple approaches. Ex vivo and in vivo genome editing platforms have been tested primarily on MSPI and MPSII, with in vivo approaches having reached clinical testing in both diseases. Though we still await proof of efficacy in humans, the therapeutic tools established for these two diseases should pave the way for other mucopolysaccharidoses. Herein, we review the current preclinical and clinical development studies, using genome editing as a therapeutic approach for these diseases. The development of new genome editing platforms and the variety of genetic modifications possible with each tool provide potential applications of genome editing for mucopolysaccharidoses, which vastly exceed the potential of current approaches. We expect that in a not-so-distant future, more genome editing-based strategies will be established, and individual diseases will be treated through multiple approaches.<\/jats:p>","DOI":"10.3390\/ijms21020500","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T03:20:22Z","timestamp":1579058422000},"page":"500","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Genome Editing for Mucopolysaccharidoses"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0554-0295","authenticated-orcid":false,"given":"Edina","family":"Poletto","sequence":"first","affiliation":[{"name":"Gene Therapy Center, Hospital de Clinicas de Porto Alegre, Porto Alegre 90035-007, Brazil"},{"name":"Post-Graduate Program in Genetics and Molecular Biology, Universidade Federal do Rio Grande do Sul, Porto Alegre 91501-970, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Baldo","sequence":"additional","affiliation":[{"name":"Gene Therapy Center, Hospital de Clinicas de Porto Alegre, Porto Alegre 90035-007, Brazil"},{"name":"Post-Graduate Program in Genetics and Molecular Biology, Universidade Federal do Rio Grande do Sul, Porto Alegre 91501-970, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6740-1154","authenticated-orcid":false,"given":"Natalia","family":"Gomez-Ospina","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1590\/S1415-47572012000600006","article-title":"Mucopolysacccharidoses: From understanding to treatment, a century of discoveries","volume":"35","author":"Giugliani","year":"2012","journal-title":"Genet. Mol. Boil."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/508294","article-title":"Mutations in TMEM76* Cause Mucopolysaccharidosis IIIC (Sanfilippo C Syndrome)","volume":"79","author":"Seyrantepe","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","article-title":"Hurler and Hunter syndromes: Mutual correction of the defect in cultured fibroblasts","volume":"162","author":"Fratantoni","year":"1968","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17425247.2014.880689","article-title":"Gene delivery strategies for the treatment of mucopolysaccharidoses","volume":"11","author":"Baldo","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/dmcn.13600","article-title":"Treatment strategies for lysosomal storage disorders","volume":"60","author":"Beck","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Christensen, C.L., Ashmead, R.E., and Choy, F.Y.M. (2019). Cell and Gene Therapies for Mucopolysaccharidoses: Base Editing and Therapeutic Delivery to the CNS. Diseases, 7.","DOI":"10.3390\/diseases7030047"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.tig.2018.05.004","article-title":"Gene Editing on Center Stage","volume":"34","author":"Bak","year":"2018","journal-title":"Trends Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e00471","DOI":"10.7554\/eLife.00471","article-title":"RNA-programmed genome editing in human cells","volume":"2","author":"Jinek","year":"2013","journal-title":"eLife"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nbt.3852","article-title":"Genome-wide target specificities of CRISPR RNA-guided programmable deaminases","volume":"35","author":"Kim","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.omtm.2018.08.003","article-title":"Disruption of the BCL11A Erythroid Enhancer Reactivates Fetal Hemoglobin in Erythroid Cells of Patients with beta-Thalassemia Major","volume":"10","author":"Psatha","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1126\/scitranslmed.aan8081","article-title":"Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy","volume":"9","author":"Amoasii","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/mt.2013.111","article-title":"Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients","volume":"21","author":"Ousterout","year":"2013","journal-title":"Mol Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature20134","article-title":"CRISPR\/Cas9 beta-globin gene targeting in human haematopoietic stem cells","volume":"539","author":"Dever","year":"2016","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"360ra134","DOI":"10.1126\/scitranslmed.aaf9336","article-title":"Selection-free genome editing of the sickle mutation in human adult hematopoietic stem\/progenitor cells","volume":"8","author":"DeWitt","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-018-0050-6","article-title":"p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells","volume":"24","author":"Ihry","year":"2018","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13073-015-0215-6","article-title":"Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing","volume":"7","author":"Robert","year":"2015","journal-title":"Genome Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nbt.3190","article-title":"Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining","volume":"33","author":"Maruyama","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nbt.3198","article-title":"Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells","volume":"33","author":"Chu","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbiotec.2011.03.023","article-title":"Over-expression of RAD51 or RAD54 but not RAD51\/4 enhances extra-chromosomal homologous recombination in the human sarcoma (HT-1080) cell line","volume":"154","author":"Yu","year":"2011","journal-title":"J. Biotechnol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/s41467-018-03475-7","article-title":"CtIP fusion to Cas9 enhances transgene integration by homology-dependent repair","volume":"9","author":"Charpentier","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.stem.2019.02.019","article-title":"Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response","volume":"24","author":"Schiroli","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"21264","DOI":"10.1038\/srep21264","article-title":"Enrichment of G2\/M cell cycle phase in human pluripotent stem cells enhances HDR-mediated gene repair with customizable endonucleases","volume":"6","author":"Yang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e04766","DOI":"10.7554\/eLife.04766","article-title":"Enhanced homology-directed human genome engineering by controlled timing of CRISPR\/Cas9 delivery","volume":"3","author":"Lin","year":"2014","journal-title":"Elife"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e33761","DOI":"10.7554\/eLife.33761","article-title":"Covalent linkage of the DNA repair template to the CRISPR-Cas9 nuclease enhances homology-directed repair","volume":"7","author":"Savic","year":"2018","journal-title":"Elife"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/MOH.0000000000000385","article-title":"The changing landscape of gene editing in hematopoietic stem cells: A step towards Cas9 clinical translation","volume":"24","author":"Dever","year":"2017","journal-title":"Curr. Opin. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1089\/hum.2017.149","article-title":"Genome and Epigenome Editing to Treat Disorders of the Hematopoietic System","volume":"28","author":"Mussolino","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1016\/S0021-9258(19)85586-2","article-title":"Biosynthesis of lysosomal enzymes in fibroblasts. Phosphorylation of mannose residues","volume":"255","author":"Hasilik","year":"1980","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): A phase 3 randomised placebo-controlled study","volume":"37","author":"Hendriksz","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","article-title":"Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase","volume":"115","author":"Harmatz","year":"2005","journal-title":"Pediatrics"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","article-title":"Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"144","author":"Harmatz","year":"2004","journal-title":"J. Pediatr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ymgme.2018.02.006","article-title":"A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease","volume":"123","author":"Harmatz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/MOP.0b013e32834c20d9","article-title":"Enzyme replacement therapy for lysosomal storage diseases","volume":"23","author":"Lachmann","year":"2011","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: Considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1021\/acs.molpharmaceut.6b01166","article-title":"Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody\u2013Iduronidase Fusion Protein","volume":"14","author":"Boado","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_48","first-page":"S124","article-title":"Novel treatments and future perspectives: Outcomes of intrathecal drug delivery","volume":"47","author":"Dickson","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16390","article-title":"The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: A longitudinal cohort study of people with lysosomal storage disorders","volume":"16","author":"Wyatt","year":"2012","journal-title":"Health Technol. Assess."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mt.2009.150","article-title":"Strategies to Modulate Immune Responses: A New Frontier for Gene Therapy","volume":"17","author":"Arruda","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Coutinho, M.F., Santos, J.I., and Alves, S. (2016). Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17071065"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","article-title":"An open-label, noncomparative study of miglustat in type I Gaucher disease: Efficacy and tolerability over 24 months of treatment","volume":"27","author":"Pastores","year":"2005","journal-title":"Clin. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jpeds.2011.04.040","article-title":"Evaluation of Miglustat Treatment in Patients with Type III Mucopolysaccharidosis: A Randomized, Double-Blind, Placebo-Controlled Study","volume":"159","author":"Guffon","year":"2011","journal-title":"J. Pediatr."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Derrick-Roberts, A.L.K., Jackson, M.R., Pyragius, C.E., and Byers, S. (2017). Substrate Deprivation Therapy to Reduce Glycosaminoglycan Synthesis Improves Aspects of Neurological and Skeletal Pathology in MPS I Mice. Diseases, 5.","DOI":"10.3390\/diseases5010005"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ymgme.2009.06.013","article-title":"Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice","volume":"98","author":"Malinowska","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.22643","article-title":"Genistein in Sanfilippo disease: A randomized controlled crossover trial","volume":"71","author":"Valstar","year":"2012","journal-title":"Ann. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1750-1172-7-102","article-title":"Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: A prospective, open-label non-inferiority study","volume":"7","author":"Cox","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-Mediated In Vivo Gene Therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_60","first-page":"442","article-title":"Adeno-associated virus vector integration","volume":"11","author":"Deyle","year":"2009","journal-title":"Curr. Opin. Mol. Ther"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/petr.12109","article-title":"Outcomes of haematopoietic stem cell transplantation for inherited metabolic disorders: A report from the Australian and New Zealand Children\u2019s Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry","volume":"17","author":"Mitchell","year":"2013","journal-title":"Pediatr. Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","article-title":"Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: A nationwide survey in Japan","volume":"107","author":"Tanaka","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jpeds.2008.11.005","article-title":"Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy","volume":"154","author":"Wynn","year":"2009","journal-title":"J. Pediatr."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1056\/NEJMp048084","article-title":"Advances in the treatment of mucopolysaccharidosis type I","volume":"350","author":"Muenzer","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ymgme.2012.07.016","article-title":"An exploratory study of brain function and structure in mucopolysaccharidosis type I: Long term observations following hematopoietic cell transplantation (HCT)","volume":"107","author":"Shapiro","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01241398-200401000-00019","article-title":"Musculoskeletal manifestations of Hurler syndrome: Long-term follow-up after bone marrow transplantation","volume":"24","author":"Weisstein","year":"2004","journal-title":"J. Pediatr. Orthop."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jpeds.2009.07.005","article-title":"Guidelines for the Management of Mucopolysaccharidosis Type I","volume":"155","author":"Martins","year":"2009","journal-title":"J. Pediatr."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jmedgenet-2015-103322","article-title":"Clinical course of sly syndrome (mucopolysaccharidosis type VII)","volume":"53","author":"Montano","year":"2016","journal-title":"J. Med. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2015.09.011","article-title":"Hematopoietic stem cell transplantation for Morquio A syndrome","volume":"117","author":"Yabe","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF00710053","article-title":"Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation","volume":"18","author":"Shapiro","year":"1995","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1023\/A:1005525931994","article-title":"Long-term follow-up following bone marrow transplantation for Hunter disease","volume":"22","author":"Vellodi","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ymthe.2017.03.025","article-title":"Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications","volume":"25","author":"Biffi","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1089\/hum.2016.068","article-title":"Preclinical testing of the safety and tolerability of LV-mediated above normal alpha-L-iduronidase expression in murine and human hematopoietic cells using toxicology and biodistribution GLP studies","volume":"27","author":"Visigalli","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","article-title":"Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model","volume":"116","author":"Visigalli","year":"2010","journal-title":"Blood"},{"key":"ref_75","first-page":"1","article-title":"Ex-Vivo Gene Therapy for Hurler Disease: Initial Results from a Phase I\/II Clinical Study","volume":"27","author":"Gentner","year":"2019","journal-title":"Mol. Ther"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.hoc.2017.06.009","article-title":"Integrating Vectors for Gene Therapy and Clonal Tracking of Engineered Hematopoiesis","volume":"31","author":"Biasco","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.ymthe.2018.03.002","article-title":"Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing","volume":"26","author":"Laoharawee","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ymthe.2018.10.018","article-title":"ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome","volume":"27","author":"Ou","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_79","first-page":"S104","article-title":"CHAMPIONS: A phase 1\/2 clinical trial with dose escalation of SB-913 ZFN-mediated in vivo human genome editing for treatment of MPS II (Hunter syndrome)","volume":"126","author":"Muenzer","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nbt1018-907","article-title":"Sangamo\u2019s landmark genome editing trial gets mixed reception","volume":"36","author":"Sheridan","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_81","first-page":"S68","article-title":"EMPOWERS: A phase 1\/2 clinical trial of SB-318 ZFN-mediated in vivo human genome editing for treatment of MPS I (Hurler syndrome)","volume":"126","author":"Harmatz","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.gene.2018.08.004","article-title":"CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts","volume":"678","author":"Schuh","year":"2018","journal-title":"Gene"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/cge.13224","article-title":"Worldwide distribution of common IDUA pathogenic variants","volume":"94","author":"Poletto","year":"2018","journal-title":"Clin. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2018.08.031","article-title":"In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR\/Cas9 system","volume":"288","author":"Schuh","year":"2018","journal-title":"J Control Release"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Schuh, R.S., Gonzalez, E.A., Tavares, A.M.V., Seolin, B.G., Elias, L.S., Vera, L.N.P., Kubaski, F., Poletto, E., Giugliani, R., and Teixeira, H.F. Neonatal nonviral gene editing with the CRISPR\/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice. Gene Ther., 2019.","DOI":"10.1038\/s41434-019-0113-4"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nbt.4219","article-title":"Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice","volume":"36","author":"Wang","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: Results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Boil. Blood Marrow Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jcyt.2015.03.609","article-title":"Cord blood is the optimal graft source for the treatment of pediatric patients with lysosomal storage diseases: Clinical outcomes and future directions","volume":"17","author":"Aldenhoven","year":"2015","journal-title":"Cytotherapy"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future","volume":"25","author":"Taylor","year":"2019","journal-title":"Boil. Blood Marrow Transplant."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1038\/s41467-019-11962-8","article-title":"Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I","volume":"10","author":"Scharenberg","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nbt.3290","article-title":"Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells","volume":"33","author":"Hendel","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6978303","DOI":"10.1155\/2019\/6978303","article-title":"Induced Pluripotent Stem Cell Derivation and Ex Vivo Gene Correction Using a Mucopolysaccharidosis Type 1 Disease Mouse Model","volume":"2019","author":"Miki","year":"2019","journal-title":"Stem Cells Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejpb.2017.10.017","article-title":"Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR\/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers","volume":"122","author":"Schuh","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1038\/mtna.2014.64","article-title":"COSMID: A Web-based Tool for Identifying and Validating CRISPR\/Cas Off-target Sites","volume":"3","author":"Cradick","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nbt.3101","article-title":"Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases","volume":"33","author":"Frock","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nbt.1948","article-title":"An unbiased genome-wide analysis of zinc-finger nuclease specificity","volume":"29","author":"Gabriel","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1101\/gr.219089.116","article-title":"Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration","volume":"27","author":"Kim","year":"2017","journal-title":"Genome Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nmeth.3284","article-title":"Digenome-seq: Genome-wide profiling of CRISPR-Cas9 off-target effects in human cells","volume":"12","author":"Kim","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nmeth.4278","article-title":"CIRCLE-seq: A highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets","volume":"14","author":"Tsai","year":"2017","journal-title":"Nat. Methods"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-1-4939-7306-4_14","article-title":"Genome-Wide Profiling of DNA Double-Strand Breaks by the BLESS and BLISS Methods","volume":"1672","author":"Mirzazadeh","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Giannoukos, G., Ciulla, D.M., Marco, E., Abdulkerim, H.S., Barrera, L.A., Bothmer, A., Dhanapal, V., Gloskowski, S.W., Jayaram, H., and Maeder, M.L. (2018). UDiTaS, a genome editing detection method for indels and genome rearrangements. BMC Genom., 19.","DOI":"10.1186\/s12864-018-4561-9"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","article-title":"A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells","volume":"24","author":"Vakulskas","year":"2018","journal-title":"Nat. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","article-title":"Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population","volume":"10","author":"Simhadri","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/2\/500\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:05:04Z","timestamp":1760364304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/2\/500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":107,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["ijms21020500"],"URL":"https:\/\/doi.org\/10.3390\/ijms21020500","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]}}}